Docoh
Loading...
Sign up Log in

AGN Allergan

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands andbest-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology. As part of its approach to delivering innovation for better patient care, Allergan has built one of the broadest pharmaceutical and device research and development pipelines in the industry.

Company profile

Ticker
AGN
Exchange
NYSE
Website
www.allergan.com
CEO
Brenton L. Saunders
Employees
Incorporated
Ireland
Location
Ireland
Fiscal year end
Dec 31
Sector
Health Technology > Pharmaceuticals: Generic
Industry (SIC)
Pharmaceutical Preparations
Pfizer • Merck & Co • Johnson & Johnson • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Warner Chilcott • Abbvie • Celgene ...
Former names
Actavis Ltd, Actavis plc
SEC CIK
0001578845
Corporate docs

AGN stock data

(
)

Press releases

Pro users get this 30m faster
Worldwide Facial Injectable Industry to 2025 - by Type, Generation, End-user and Geography
24 Feb 21
Dublin, Feb. 24, 2021 (GLOBE NEWSWIRE) -- The "Facial Injectable Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering. The facial injectable market is projected

Calendar

7 May 20
28 Feb 21
31 Dec 21

Recent insider trades

AGN insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
8 May 20 Coughlin Christopher J Ordinary Shares, par value $0.0001 Sale back to company Dispose D No No 0 16,532 0 0
8 May 20 Coughlin Christopher J Ordinary Shares, par value $0.0001 Sale back to company Dispose D Yes No 0 9,538 0 16,542
8 May 20 Coughlin Christopher J Ordinary Shares, par value $0.0001 Sale back to company Dispose D Yes No 0 471 0 26,080
8 May 20 Coughlin Christopher J Stock Options Ordinary Shares Sale back to company Dispose D No No 70.79 9,446 668.68K 0
8 May 20 Coughlin Christopher J Stock Options Ordinary Shares Sale back to company Dispose D No No 73.14 3,691 269.96K 0
8 May 20 Coughlin Christopher J Stock Options Ordinary Shares Sale back to company Dispose D No No 90.22 2,790 251.71K 0
8 May 20 William Meury RSU Sale back to company Dispose D No No 0 25,201 0 0
8 May 20 William Meury Ordinary Shares, par value $0.0001 Sale back to company Dispose D No No 0 7,434 0 0
8 May 20 William Meury Performance Stock Units Ordinary Shares Sale back to company Dispose D No No 0 26,506 0 0
8 May 20 William Meury Stock Options Ordinary Shares Sale back to company Dispose D No No 196.16 12,304 2.41M 0
Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

AGN institutional ownership history Ownership history
0.0% owned by funds/institutions
13F holders
 Current Prev Q Change
Total holders 3 5 -40.0%
Opened positions 2 2 –
Closed positions 4 6 -33.3%
Increased positions 0 0
Reduced positions 0 1 EXIT
13F shares
 Current Prev Q Change
Total value 3.06M 21.89M -86.0%
Total shares 17.31K 222.32K -92.2%
Total puts 0 0
Total calls 0 0
Total put/call ratio – – –
Largest owners
 Shares Value Change
TMP Tompkins Financial 17.04K $3.02M NEW
Founders Capital Management 276 $46K NEW
IFP Advisors 0 $0
Largest transactions
 Shares Bought/sold Change
Ashburton 0 -195.5K EXIT
New Mexico Educational Retirement Board 0 -23.73K EXIT
TMP Tompkins Financial 17.04K +17.04K NEW
Belpointe Asset Management 0 -2.34K EXIT
JDC-JSC 0 -750 EXIT
Founders Capital Management 276 +276 NEW
IFP Advisors 0 0
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Akorn • TherapeuticsMD • AMGEN • Hologic • Veru • Vivus • Royalty Pharma • Palatin • Integra Lifesciences • IRIDEX
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: alpha, API, argument, Asia, AstraZeneca, autoimmune, behavior, biodegradable, broadest, built, buyer, Cadila, certainty, chain, composition, confirm, confirming, contamination, continent, Coolsculpting, CoolTone, Cream, cystic, declare, deliver, detailing, discontinuation, discontinued, distancing, Durysta, electronic, enrolling, environment, enzyme, Esthetique, evolve, exocrine, experienced, Gedeon, genericization, glaucoma, globe, half, home, hypertension, inability, indirectly, inhibitor, innovation, insufficiency, intracameral, intraocular, IOP, Ireland, Lab, Lazeo, LIBOR, lifetime, local, logistical, losing, medial, minute, mitigate, Nestle, OAG, ocular, OHT, outbreak, Pacific, pancreatic, pandemic, patient, pressure, rebate, recession, recovery, relationship, remotely, reply, Richter, satisfaction, Science, shelter, spent, spread, strain, susceptible, suspended, temporarily, Ubrelvy, unemployment, Viokace, Vital
Removed: absence, acceleration, acid, add, adjunctive, advancement, affirming, Akorn, Akron, Apotex, appellate, applied, Argentum, asserting, authorize, automatically, back, binding, BioMed, Biomedical, Body, bound, buy, calculate, calculated, capitalized, capitalizing, Center, centralized, certiorari, chosen, clarify, cloud, collateralization, collateralized, commonly, computing, concurrently, Contouring, contractually, conversion, correct, corrected, Corrupt, cumulative, delaying, Delzicol, denial, denying, Depressive, dermatology, determining, Deva, disgorgement, Disorder, dozen, Easement, enablement, enacted, enforceable, Envy, equaled, equipment, equitable, error, established, estate, Europe, exemption, exercised, expedient, explicitly, Famy, fiscal, fleet, fourth, Framework, gamma, GILTI, ground, Harbor, HD, higher, hosted, immunity, implementation, implicit, implicitly, improper, incorrectly, India, Influenced, InnoPharma, institute, instrument, intent, invalidity, inventorship, issuing, joinder, LA, land, lease, leasing, Legacy, legally, lessee, lessor, Lidoderm, LifeCell, limit, Low, mandatorily, mandatory, MDD, modified, modify, noncancelable, notification, offsetting, older, opening, option, orphan, ownership, package, pattern, Pennsylvania, pension, permission, pertaining, Pharmacal, pivotal, plant, Plastic, postretirement, practical, preferred, prepaid, preventing, privately, pronouncement, prospectively, purpose, qualify, Racketeer, rapastinel, rating, reaching, real, receptor, reclassification, reclassify, recognition, redeemed, refinancing, released, remove, renew, renewal, rental, Replacement, represented, requiring, residual, restitution, resurfacing, retinoic, retired, retrospective, retrospectively, revaluation, reversing, RORyt, ROU, SA, scaling, shortened, skin, Slayback, software, sovereign, standalone, statutory, stranded, substantive, substitute, Subtopic, suit, supplier, Surgery, suspension, Targeted, Taxed, TCJA, terminate, Therapy, threshold, topline, treble, tribal, TWi, Ubrogepant, unrelated, updated, USD, vendor, VI, Vitae, withdraw, withdrew, writ
From filing 10-Q 2020 Q1

Financial reports

View all
10-Q
2020 Q1
Quarterly report
7 May 20
10-K/A
2019 FY
Annual report (amended)
29 Apr 20
10-K
2019 FY
Annual report
18 Feb 20
10-Q
2019 Q3
Quarterly report
5 Nov 19
10-Q
2019 Q2
Quarterly report
8 Aug 19
10-Q
2019 Q1
Quarterly report
7 May 19
10-K
2018 FY
Annual report
14 Feb 19
10-Q
2018 Q3
Quarterly report
31 Oct 18
10-Q
2018 Q2
Quarterly report
2 Aug 18
10-Q/A
2018 Q1
Quarterly report (amended)
25 May 18

Current reports

View all
8-K
Material Modifications to Rights of Security Holders
14 May 20
8-K
AbbVie Inc. Completes Acquisition of Allergan plc
8 May 20
8-K
Announcement relating to the outcome of the Court Sanction Hearing
6 May 20
8-K
Temporary Suspension of Trading Under Registrant's Employee Benefit Plans
21 Apr 20
8-K
AbbVie and Allergan Sign Consent Decree Agreement with Federal Trade Commission Staff on Pending Transaction
17 Mar 20
8-K
AbbVie and Allergan Receive Final European Approval to Close Pending Transaction
3 Mar 20
8-K
Allergan Reports Fourth Quarter and Full-Year 2019 Financial Results
10 Feb 20
8-K
AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep
27 Jan 20
8-K
Third Quarter 2019 Financial Results—Frequently Asked Questions
5 Nov 19
8-K
Allergan Reports Third Quarter 2019 Financial Results
5 Nov 19

Registration and prospectus

View all
15-12B
Securities registration termination
21 May 20
POS AM
Prospectus update (post-effective amendment)
14 May 20
POS AM
Prospectus update (post-effective amendment)
14 May 20
POS AM
Prospectus update (post-effective amendment)
14 May 20
POS AM
Prospectus update (post-effective amendment)
14 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
14 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
14 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
14 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
14 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
14 May 20

Proxies

View all
DEFA14A
Additional proxy soliciting materials
3 Oct 19
DEFA14A
Additional proxy soliciting materials
27 Sep 19
DEFM14A
Proxy related to merger
16 Sep 19
DEFA14A
Additional proxy soliciting materials
10 Sep 19
PREM14A
Preliminary proxy related to merger
12 Aug 19
DEFA14A
Additional proxy soliciting materials
12 Jul 19
DEFA14A
Additional proxy soliciting materials
8 Jul 19
DEFA14A
Additional proxy soliciting materials
1 Jul 19
DEFA14A
Additional proxy soliciting materials
28 Jun 19
DEFA14A
Additional proxy soliciting materials
28 Jun 19

Other

View all
EFFECT
Notice of effectiveness
19 May 20
EFFECT
Notice of effectiveness
19 May 20
EFFECT
Notice of effectiveness
19 May 20
EFFECT
Notice of effectiveness
19 May 20
SD
Conflict minerals disclosure
23 May 19
SD
Conflict minerals disclosure
31 May 18
SD
Conflict minerals disclosure
30 May 17
UPLOAD
Letter from SEC
22 Feb 17
CORRESP
Correspondence with SEC
13 Feb 17
UPLOAD
Letter from SEC
6 Feb 17

Ownership

View all
4
Allergan / Nesli Basgoz ownership change
12 May 20
4
Allergan / Joseph H Boccuzi ownership change
12 May 20
4
Allergan / ROBERT J HUGIN ownership change
11 May 20
4
Allergan / CHRIS W BODINE ownership change
11 May 20
4
Allergan / James DArecca ownership change
11 May 20
4
Allergan / Adriane M Brown ownership change
11 May 20
4
Allergan / A Robert D Bailey ownership change
11 May 20
4
Allergan / THOMAS C FREYMAN ownership change
11 May 20
4
Allergan / MATTHEW M WALSH ownership change
11 May 20
4
Allergan / CAROL ANTHONY DAVIDSON ownership change
11 May 20

Patents

View all
APP
Utility
Formation of Bone
11 Feb 21
Compositions and methods for inducing or promoting repair of a bone fracture.
APP
Utility
Method for Stabilizing a Toxin
11 Feb 21
Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients.
GRANT
Utility
Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin
9 Feb 21
Methods for treating melanin-related afflictions of the skin, such as hyperpigmentation, are provided.
GRANT
Utility
Androgen composition for treating an ophthalmic condition
2 Feb 21
The disclosure provides compositions for treating an ocular condition.
GRANT
Utility
Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
2 Feb 21
Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and optionally including proteins.

Reddit threads

Pro users get this 30m faster